The final reporting period (FRP) in ADLIFE covered from May 1st, 2023 to November 30th, 2024. This period was very active in work packages (WPs) 1, 2, 3, 8, 9, and 10.WPs 4, 5, 6, and 7 were completed during the 2nd periodic report (2nd PR). However, since technical and operational requirements related to the integration, testing and piloting of the ADLIFE platforms were requested, WP4 and WP5 continued to support pilot preparation activities.
The project ended in November 2024 instead of June 2024 as initially designed, with the corresponding extension in the timeline for all active tasks, milestones, deliverables and reporting periods.
During this period, ADLIFE has addressed the challenge of providing appropriate, timely, and targeted care to patients with advanced chronic diseases (ACDs) in real-world settings. Leveraging innovative digital solutions (ADLIFE Toolbox), the project has demonstrated its ability to adapt and respond to the diverse needs of patients and caregivers. This adaptability highlights the potential of ADLIFE to enhance healthcare delivery and positions it as a framework for replicating integrated care solutions across different healthcare systems, while ensuring trust in data security and interoperability.
The ADLIFE intervention has been deployed across various pilot sites, each with different levels of integration and implementation. The diversity in pilot scenarios demonstrates the adaptability of the ADLIFE intervention, reflecting the varied healthcare systems and regions in which it was implemented, highlighting the flexibility of the model to be applied across different contexts.
The evaluation of the ADLIFE intervention focused on the following aspects: effectiveness, implementation, technology acceptance and socio-economic.
Dissemination
During FRP of the project, ADLIFE delivered ten oral and one workshop presentations at international conferences related to the project; and two peer-reviewed scientific publications were published. During the whole project, a total of six peer-reviewed scientific journal articles were published, two pre-prints that provided early insights into ongoing research. Also, two academic theses highlighted important work associated with ADLIFE, collectively reflecting the project's dedication to advancing knowledge in the field. These efforts underscore the consortium's commitment to maximizing the visibility and impact of project results and thus is reflected in the additional effort required in dissemination and communication.
Exploitation
The ADLIFE project has delivered a significant number of exploitable results including key exploitable results, knowledge assets, educational resources, and project materials. In addition, the project generated valuable expertise across a range of critical areas, such as personalized care planning, change management strategies, shared decision-making, patient empowerment, ICT development, and large-scale implementation.
The implementation and scaling-up of ADLIFE are influenced by diverse factors operating at multiple levels. These include macro-level considerations such as health system policies and regulations, meso-level factors at the organizational level, and micro-level dynamics involving human and technological aspects. Contextual factors at these different levels need to be thoroughly assessed and addressed to ensure successful adoption and sustained use of the ADLIFE toolbox.
Next steps towards exploitation
As a next step towards exploitation, achieving certification as a Medical Device under the Medical Device Regulation (MDR) is an important step forward. This certification will ensure regulatory compliance and enable the safe and reliable implementation of the ADLIFE Toolbox in clinical settings. ADLIFE is currently exploring options to support the process of obtaining MDR certification.
